Drug
Olatorepatide
Olatorepatide: highest development phase Phase 2, developed by Regeneron. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Regeneron
Trials
| Drug | Phase | Indication |
|---|---|---|
| Olatorepatide NCT07830329 | Phase 2 | Hidradenitis Suppurativa |
| Olatorepatide NCT07685808 | Phase 2 | Overweight or Obesity |
Latest
No recent events.
Follow Olatorepatide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.